Eledon Pharmaceuticals financials
$2.50−5.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$83.3M | -$70.6M | -$43.0M | -$88.4M | -$36.9M |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M | -$34.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.52 | $-0.66 | $-4.73 | $-6.16 | $-2.33 |
| EBITDA | -$83.3M | -$70.6M | -$43.0M | -$39.8M | -$36.9M |
| Operating cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | -$28.9M |
| Free cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | — |
| Diluted shares | 81.8M | 48.5M | 24.6M | 14.3M | 14.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $22.8M | $20.5M | $4.6M | $56.4M | $84.8M |
| Short-term investments | $110.5M | $119.6M | $46.5M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $169.0M | $177.4M | $89.1M | $92.8M | $170.5M |
| Total liabilities | $32.2M | $59.3M | $81.9M | $8.6M | $6.6M |
| Shareholders' equity | $81.1M | $62.4M | -$48.5M | $84.2M | $164.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology